Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

The user is considering starting Minoxidil and is looking for a topical solution to combine with it. They are confused about which product to prioritize among options like RU58841, Pyrilutamide, FinaTopic, and DutaTopic.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

A user wants to add cetirizine tablets to their minoxidil bottle and asks how many 10mg tablets to crush for a 100ml bottle. They seek advice on the correct dosage.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

The conversation is about using Winlevi 1% cream, Pyri (Koshine) 0.5%, and minoxidil for hair loss treatment. The user is hopeful for results with Winlevi but is sensitive to 5AR blockers.

A Korean laser helmet increases hair growth by 44% compared to a placebo. Users discuss its cost-effectiveness, clinical support, and compare it to treatments like finasteride and minoxidil, focusing on wavelength and energy density.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

OP used HIMS hybrid tablets containing 1.1mg finasteride, 3mg minoxidil, and 2.5mg biotin, showing significant hair regrowth after initial shedding. OP experienced no side effects and plans to continue treatment.

A 45-year-old user shared progress pictures after 4 months of using a topical gel with 2.5% finasteride and 5% minoxidil once daily. The second picture shows significant improvement in hair growth.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

The user reported positive results using KX-826 0.5% twice daily for hair loss, noting progress in the temple area with no systemic side effects. They avoided finasteride and minoxidil due to concerns about side effects and inconvenience, respectively, and used ketoconazole shampoo for seborrheic dermatitis.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.